| Title | Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis |
| Authors | Sun, Feng Yu, Kai Wu, Shanshan Zhang, Yuan Yang, Zhirong Shi, Luwen Ji, Linong Zhan, Siyan |
| Affiliation | Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China. Peking Univ, Int Res Ctr Med Adm, Beijing 100191, Peoples R China. Shihezi Univ, Coll Med, Dept Prevent Med, Shihezi 832002, Peoples R China. Tianjin Fifth Cent Hosp, Dept Orthoped, Tianjin 300450, Peoples R China. Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China. Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, 38 Xueyuan Rd, Beijing 100191, Peoples R China. |
| Keywords | Glucagon-like peptide-1 receptor agonists Cardiovascular safety Efficacy Network meta-analysis Type 2 diabetes mellitus RANDOMIZED CLINICAL-TRIALS MYOCARDIAL-INFARCTION ANTIDIABETIC AGENTS EXENATIDE TWICE PARALLEL-GROUP LIRAGLUTIDE THERAPIES INSULIN EFFICACY DISEASE |
| Issue Date | 2012 |
| Publisher | diabetes research and clinical practice |
| Citation | DIABETES RESEARCH AND CLINICAL PRACTICE.2012,98,(3),386-395. |
| Abstract | Aims: Integrating evidence from all randomized controlled trials (RCTs) of glucagon-like peptide-1 receptor agonists (GLP-1s) to assess the safety of cardiovascular disease (CVD) and efficacy of glycemic control. Methods: Besides performing pairwise meta-analysis, network meta-analysis of all RCTs was used to combine direct and indirect estimates of the effect of GLP-1 with placebo, active comparator drugs (ACD), or another GLP-1 agent with treatment duration >8 weeks in T2DM patients, 15,883 for CVD safety from 45 RCTs and 14,136 for glycemic control from 36 RCTs. Results: For CVD safety, both of the results from pairwise and network meta-analysis failed to demonstrate significant difference between any two comparators. For glycemic control, the effect of any GLP-1 was better than placebo, but no difference was found between GLP-1s. We also found that liraglutide was the only GLP-1 drug shown to be more effective on improving glycemic control than ACD and exenatide. The results based on direct or indirect estimates were similar for two outcomes. Conclusion: Our network meta-analysis provides a complete picture of the associations between GLP-1s, ACD and placebo on CVD safety and glycemic control. The GLP-1s are promising candidates for the treatment of T2DM, but more long-term trials are needed to confirm potential CVD safety. (C) 2012 Elsevier Ireland Ltd. All rights reserved. |
| URI | http://hdl.handle.net/20.500.11897/191955 |
| ISSN | 0168-8227 |
| DOI | 10.1016/j.diabres.2012.09.004 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 公共卫生学院 人民医院 |
